UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48

Benzinga · 1d ago
UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.